ArticleAnalytical chemistry2026
A Reversible ATR-FTIR Biosensor with Single-Residue Sensitivity.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infrared spectroscopy provides label-free access to protein structure information with high sensitivity. Challenges in infrared spectroscopy include artifacts arising from temperature changes, baseline drifts, and the strong water absorption, especially in difference spectroscopy, where signals are orders of magnitude smaller than the total absorbance. Previously, we introduced an ATR-based immuno-infrared sensor (iRS) based on sophisticated surface chemistry. This provides a stable platform for covalent protein immobilization and allows its application with body fluids such as cerebrospinal fluid or blood without unspecific background. It detects misfolding of small amounts of antigen (Aβ or α-synuclein) by binding to an antibody or antibody fragment, which allows for the diagnosis of various neurodegenerative diseases. Here, we extend this platform by introducing reversible binding via the NColE7/Im7 pair. Im7-tagged proteins are captured with subpicomolar affinity and quantitatively released under mild conditions (high salt or low pH), allowing repeated capture-regeneration cycles with continuous spectral monitoring of the Im7 fusion protein. Using an Im7-antibody Fab fusion protein, we present a reusable immuno-IR sensor that enables multiple measurements on the same surface. For example, different antibodies can be used for differential screening. Using alternating Im7 protein attachments to the internal reflection element, we further compare Im7 single point mutants to wild-type Im7 to resolve infrared signatures of specific amino acid substitutions. Difference spectra reveal the distinct tyrosine absorption associated with either the introduction or removal of a single tyrosine residue, providing a proof-of-concept for single-residue sensitivity in infrared difference spectroscopy enabled by complete protein exchange instead of induced perturbations on the same protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.